A Phase 3 interventional study of Bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 2 that started in 2005, is one of 7 in phase 3, and was the 5th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 37 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 9 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 41st largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2005, is one of 31 in phase 3, and was the 8th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
Drug: Bosentan
32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
Also known as: Ro 47-0203, Tracleer
Change From Baseline to End of Study (EOS) in Height for Age.
In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula: Z-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population
Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Change From Baseline to End of Study (EOS) in Body Weight
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.
Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Change From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP)
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Change From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP)
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Change From Baseline to End of Study (EOS) in Pulse Rate
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.
Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Proportion of Patients With Treatment-emergent Liver Function Abnormalities
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes. Proportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.
Time frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average
Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities. Proportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.
Time frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment
Time frame: From the first study drug administration in FUTURE 1, for an average of 31 months
36 Children ( \>= 2 years and \< 12 years) with idiopathic or familial pulmonary arterial hypertension were recruited from 11 centers across Europe and USA and enrolled in the FUTURE 1 trial (baseline). Only patients who completed FUTURE 1 (n=34) could be enrolled in FUTURE 2. Enrollment in FUTURE 2 started August 23, 2005.
| Milestone | Patients With Previous Bosentan | Bosentan-naive Patients |
|---|---|---|
| Started | 15 | 21 |
| Enrollment in future 2 (f-2) | 13 | 20 |
| Completed | 8 | 8 |
| Not completed | 7 | 13 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: F-1 completed but not enrolled in f-2 | 1 | 0 |
| Withdrew: Administrative reason | 0 | 5 |
| Withdrew: Disease progression | 0 | 2 |
| Withdrew: Transplant | 0 | 1 |
| Withdrew: Treatment failure | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula: Z-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population
| Z-score | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Z-score at baseline | -0.8 (-3.32 to 3.72) | 0.32 (-2.62 to 1.99) | -0.64 (-3.32 to 3.72) |
| Z-score at EOS | -0.74 (-3.52 to 2.78) | -0.08 (-2.44 to 1.84) | -0.36 (-3.52 to 2.78) |
| Z-score change from baseline to EOS | -0.05 (-0.94 to 0.91) | -0.01 (-0.77 to 1.08) | -0.01 (-0.94 to 1.08) |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.
| kg | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Weight at baseline | 19.6 (12.5 to 30.2) | 21.6 (11 to 39) | 19.6 (11 to 39) |
| Weight change from baseline to EOS | 8.2 (5 to 24.8) | 8.5 (1.8 to 18.5) | 8.3 (1.8 to 24.8) |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
| mmHg | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| SBP at baseline | 101.5 (87 to 115) | 104 (79 to 121) | 102.5 (79 to 121) |
| SBP change from baseline to EOS | -10.5 (-20 to 25) | 4 (-21 to 28) | -4.5 (-21 to 28) |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
| mmHg | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| DBP at baseline | 54.5 (47 to 94) | 60 (52 to 75) | 59 (47 to 94) |
| DBP change from baseline to EOS | -5 (-34 to 19) | -2 (-13 to 20) | -3 (-34 to 20) |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.
| Beats per minutes | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Pulse rate at baseline | 87 (55 to 118) | 94.5 (62 to 133) | 88 (55 to 133) |
| Pulse rate change from baseline to EOS | -11 (-46 to 36) | -10 (-30 to 11) | -11 (-46 to 36) |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes. Proportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.
| Percentage of participants | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| ALT > 3 x ULN | 0 | 4.8 | 2.8 |
| AST > 3 x ULN | 0 | 4.8 | 2.8 |
The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities. Proportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.
| Percentage of participants | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities | 13.3 | 9.5 | 11.1 |
| Participants | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment | 1 | 5 | 6 |
Collected over From the first administration of study treatment and for an average of 31 months for frequent adverse events (up to 1 day after study treatment discontinuation), and for an average of 32 months (up to 28 days after study treatment discontinuation) for serious adverse events. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients With Previous Bosentan | — | 9/15 (60%) | 12/15 (80%) |
| Bosentan_naive Patients | — | 9/21 (42.9%) | 16/21 (76.2%) |
| Single Arm Bosentan_Total | — | 18/36 (50%) | 26/36 (72.2%) |
| Event | Patients With Previous Bosentan | Bosentan_naive Patients | Single Arm Bosentan_Total |
|---|---|---|---|
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 2/15 | 1/21 | 3/36 |
| DEVICE RELATED INFECTIONInfections and infestations | 1/15 | 2/21 | 3/36 |
| PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 1/15 | 2/21 | 3/36 |
| ABDOMINAL PAINGastrointestinal disorders | 1/15 | 0/21 | 1/36 |
| ADENOIDECTOMYSurgical and medical procedures | 1/15 | 0/21 | 1/36 |
| BACTERAEMIAInfections and infestations | 1/15 | 0/21 | 1/36 |
| BRONCHIAL OBSTRUCTIONRespiratory, thoracic and mediastinal disorders | 1/15 | 0/21 | 1/36 |
| CATHETER SITE INFECTIONInfections and infestations | 1/15 | 0/21 | 1/36 |
| CHEST PAINGeneral disorders | 1/15 | 0/21 | 1/36 |
| CONVULSIONNervous system disorders | 1/15 | 0/21 | 1/36 |
| Event | Patients With Previous Bosentan | Bosentan_naive Patients | Single Arm Bosentan_Total |
|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 1/15 | 5/21 | 6/36 |
| NASOPHARYNGITISInfections and infestations | 3/15 | 4/21 | 7/36 |
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 3/15 | 1/21 | 4/36 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/15 | 4/21 | 5/36 |
| VOMITINGGastrointestinal disorders | 0/15 | 4/21 | 4/36 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/15 | 3/21 | 3/36 |
| BRONCHITISInfections and infestations | 2/15 | 3/21 | 5/36 |
| CHEST PAINGeneral disorders | 0/15 | 3/21 | 3/36 |
| FLUSHINGVascular disorders | 1/15 | 3/21 | 4/36 |
| HEADACHENervous system disorders | 1/15 | 3/21 | 4/36 |
| Age, Continuous(Years) | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Median | 7 (3 to 10) | 7 (2 to 11) | 7 (2 to 11) |
| Age, Customized(Participants) | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| 2-3 years old | 1 | 3 | 4 |
| 4-5 years old | 3 | 6 | 9 |
| 6-11 years old | 11 | 12 | 23 |
| Sex: Female, Male(Participants) | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Female | 5 | 10 | 15 |
| Male | 10 | 11 | 21 |
| Etiology of pulmonary arterial hypertension (PAH)(Participants) | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Idiopathic PAH | 12 | 19 | 31 |
| Familial PAH | 3 | 2 | 5 |
| Duration of pulmonary arterial hypertension (PAH)(Months) | Patients With Previous Bosentan | Bosentan-naive Patients | Total |
|---|---|---|---|
| Median | 37.6 (1.2 to 82.6) | 14 (0 to 133.5) | 25.8 (0 to 133.5) |
No study locations are listed for this record.
Ran from Aug 2005 to primary completion in Oct 2011, 74 months.
Results were first posted in Mar 2017, 5 years 5 months after primary completion. A results delay was requested in Mar 2012.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 74 months is above that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Pulmonary Arterial Hypertension →